<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37445814</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>13</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>25</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>A Transcriptome Array-Based Approach Links Proteinuria and Distinct Molecular Signatures to Intrarenal Expression of Type I Interferon <i>IFNA5</i> in Lupus Nephritis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10636</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241310636</ELocationID><Abstract><AbstractText>In systemic lupus erythematosus (SLE), the relevance of non-hematopoietic sources of type I interferon in human autoimmunity has recently been recognized. Particularly, type I interferon production precedes autoimmunity in early skin lesions related to SLE. However, the relevance of intrarenal type I interferon expression has not been shown in lupus nephritis. From transcriptome array datasets, median-centered log<sub>2</sub> mRNA expression levels of IFN&#x3b1; (<i>IFNA1</i>, <i>IFNA2</i>, <i>IFNA4</i>, <i>IFNA5</i>, <i>IFNA6</i>, <i>IFNA7</i>, <i>IFNA8</i>, <i>IFNA10</i>, <i>IFNA13</i>, <i>IFNA14</i>, <i>IFNA16</i>, <i>IFNA17</i>, and <i>IFNA21</i>), IFN&#x3c9; (<i>IFNW1</i>), and IFN&#x3b2; (<i>IFNB1</i>) in lupus nephritis were extracted specifically from microdissected tubulointerstitial (<i>n</i> = 32) and glomerular compartments (<i>n</i> = 32). We found an association between proteinuria and tubulointerstitial expression of type I interferon <i>IFNA5</i> (<i>p</i> = 0.0142), while all others were not significantly associated. By contrast, no such correlation was observed between proteinuria and any type I interferon expression in the glomerular compartment in lupus nephritis. Interestingly, there was no difference between female and male patients (<i>p</i> = 0.8237) and no association between type I interferon <i>IFNA5</i> expression and kidney function or lupus nephritis progression. Finally, we identified distinct molecular signatures involved in transcriptional regulation (GLI protein-regulated transcription, IRF7 activation, and HSF1-dependent transactivation) and receptor signaling (BMP signaling and GPCR ligand binding) in association with tubulointerstitial expression of type I interferon <i>IFNA5</i> in the kidney. In summary, this transcriptome array-based approach links proteinuria to the tubulointerstitial expression of type I interferon <i>IFNA5</i> in lupus nephritis. Because type I interferon receptor subunit I antagonism has recently been investigated in active SLE, the current study further emphasizes the role of type I interferons in lupus nephritis and might also be of relevance for mechanistic studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Korsten</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6065-5680</Identifier><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, University Medical Center G&#xf6;ttingen, 37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tampe</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-4357-9863</Identifier><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, University Medical Center G&#xf6;ttingen, 37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C554324">IFNA13 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011507" MajorTopicYN="N">Proteinuria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IFNA5</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">proteinuria</Keyword><Keyword MajorTopicYN="N">type I interferon</Keyword></KeywordList><CoiStatement>P.K. has received research grants from GlaxoSmithKline and Diamed Medizintechnik GmbH, all unrelated to this paper. P.K. has received honoraria or travel support from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers-Squibb, Chugai, Galapagos, GlaxoSmithKline, Janssen-Cilag, Lilly, Novartis, and Pfizer, all unrelated to this paper. B.T. has received research grants from Evotec SE and CSL Vifor, all unrelated to this paper. B.T. has received honoraria or travel support from CSL Vifor, all unrelated to this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37445814</ArticleId><ArticleId IdType="pmc">PMC10341446</ArticleId><ArticleId IdType="doi">10.3390/ijms241310636</ArticleId><ArticleId IdType="pii">ijms241310636</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos G.C. Systemic Lupus Erythematosus. N. Engl. J. Med. 2011;365:2110&#x2013;2121. doi: 10.1056/NEJMra1100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam N.C., Ghetu M.V., Bieniek M.L. Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management. Am. Fam. Physician. 2016;94:284&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">27548593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisnevskaia L., Murphy G., Isenberg D. Systemic Lupus Erythematosus. Lancet. 2014;384:1878&#x2013;1888. doi: 10.1016/S0140-6736(14)60128-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60128-8</ArticleId><ArticleId IdType="pubmed">24881804</ArticleId></ArticleIdList></Reference><Reference><Citation>Weckerle C.E., Franek B.S., Kelly J.A., Kumabe M., Mikolaitis R.A., Green S.L., Utset T.O., Jolly M., James J.A., Harley J.B., et al. Network Analysis of Associations between Serum Interferon-Alpha Activity, Autoantibodies, and Clinical Features in Systemic Lupus Erythematosus. Arthritis Rheum. 2011;63:1044&#x2013;1053. doi: 10.1002/art.30187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30187</ArticleId><ArticleId IdType="pmc">PMC3068224</ArticleId><ArticleId IdType="pubmed">21162028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirou K.A., Lee C., George S., Louca K., Peterson M.G., Crow M.K. Activation of the Interferon-Alpha Pathway Identifies a Subgroup of Systemic Lupus Erythematosus Patients with Distinct Serologic Features and Active Disease. Arthritis Rheum. 2005;52:1491&#x2013;1503. doi: 10.1002/art.21031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21031</ArticleId><ArticleId IdType="pubmed">15880830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall J.C., Rosen A. Type I Interferons: Crucial Participants in Disease Amplification in Autoimmunity. Nat. Rev. Rheumatol. 2010;6:40&#x2013;49. doi: 10.1038/nrrheum.2009.237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2009.237</ArticleId><ArticleId IdType="pmc">PMC3622245</ArticleId><ArticleId IdType="pubmed">20046205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv L.B., Donlin L.T. Regulation of Type I Interferon Responses. Nat. Rev. Immunol. 2014;14:36&#x2013;49. doi: 10.1038/nri3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3581</ArticleId><ArticleId IdType="pmc">PMC4084561</ArticleId><ArticleId IdType="pubmed">24362405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., Notkins A.L. Immune Interferon in the Circulation of Patients with Autoimmune Disease. N. Engl. J. Med. 1979;301:5&#x2013;8. doi: 10.1056/NEJM197907053010102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197907053010102</ArticleId><ArticleId IdType="pubmed">449915</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyuan I.T., Tzeng H.T., Chen J.Y. Signaling Pathways of Type I and Type Iii Interferons and Targeted Therapies in Systemic Lupus Erythematosus. Cells. 2019;8:963. doi: 10.3390/cells8090963.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8090963</ArticleId><ArticleId IdType="pmc">PMC6769759</ArticleId><ArticleId IdType="pubmed">31450787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.M., Park S.H., Kim H.Y., Kwok S.K. A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus. Int. J. Mol. Sci. 2015;16:14158&#x2013;14170. doi: 10.3390/ijms160614158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms160614158</ArticleId><ArticleId IdType="pmc">PMC4490545</ArticleId><ArticleId IdType="pubmed">26110387</ArticleId></ArticleIdList></Reference><Reference><Citation>Goropevsek A., Holcar M., Avcin T. The Role of Stat Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus. Clin. Rev. Allergy Immunol. 2017;52:164&#x2013;181. doi: 10.1007/s12016-016-8550-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-016-8550-y</ArticleId><ArticleId IdType="pubmed">27216430</ArticleId></ArticleIdList></Reference><Reference><Citation>Sozzani S., Bosisio D., Scarsi M., Tincani A. Type I Interferons in Systemic Autoimmunity. Autoimmunity. 2010;43:196&#x2013;203. doi: 10.3109/08916930903510872.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916930903510872</ArticleId><ArticleId IdType="pubmed">20298124</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow M.K., Olferiev M., Kirou K.A. Targeting of Type I Interferon in Systemic Autoimmune Diseases. Transl. Res. 2015;165:296&#x2013;305. doi: 10.1016/j.trsl.2014.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2014.10.005</ArticleId><ArticleId IdType="pmc">PMC4306610</ArticleId><ArticleId IdType="pubmed">25468480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler D.S., Levy D.E., Darnell J.E., Jr. Two Interferon-Induced Nuclear Factors Bind a Single Promoter Element in Interferon-Stimulated Genes. Proc. Natl. Acad. Sci. USA. 1988;85:8521&#x2013;8525. doi: 10.1073/pnas.85.22.8521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.22.8521</ArticleId><ArticleId IdType="pmc">PMC282490</ArticleId><ArticleId IdType="pubmed">2460869</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy D.E., Kessler D.S., Pine R., Reich N., Darnell J.E., Jr. Interferon-Induced Nuclear Factors That Bind a Shared Promoter Element Correlate with Positive and Negative Transcriptional Control. Genes Dev. 1988;2:383&#x2013;393. doi: 10.1101/gad.2.4.383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.2.4.383</ArticleId><ArticleId IdType="pubmed">3371658</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Kaiser V., Beier E., Bechheim M., Guenthner-Biller M., Ablasser A., Berger M., Endres S., Hartmann G., Hornung V. Self-Priming Determines High Type I Ifn Production by Plasmacytoid Dendritic Cells. Eur. J. Immunol. 2014;44:807&#x2013;818. doi: 10.1002/eji.201343806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201343806</ArticleId><ArticleId IdType="pmc">PMC4523003</ArticleId><ArticleId IdType="pubmed">24338737</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao A.P., Salajegheh M., Morehouse C., Nazareno R., Jubin R.G., Jallal B., Yao Y., Greenberg S.A. Human Plasmacytoid Dendritic Cell Accumulation Amplifies Their Type 1 Interferon Production. Clin. Immunol. 2010;136:130&#x2013;138. doi: 10.1016/j.clim.2010.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2010.02.014</ArticleId><ArticleId IdType="pmc">PMC2892243</ArticleId><ArticleId IdType="pubmed">20346735</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Tsao B.P. Advances in Lupus Genetics and Epigenetics. Curr. Opin. Rheumatol. 2014;26:482&#x2013;492. doi: 10.1097/BOR.0000000000000086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000086</ArticleId><ArticleId IdType="pmc">PMC4222581</ArticleId><ArticleId IdType="pubmed">25010439</ArticleId></ArticleIdList></Reference><Reference><Citation>Postal M., Sinicato N.A., Pelicari K.O., Marini R., Costallat L.T.L., Appenzeller S. Clinical and Serological Manifestations Associated with Interferon-Alpha Levels in Childhood-Onset Systemic Lupus Erythematosus. Clinics. 2012;67:157&#x2013;162. doi: 10.6061/clinics/2012(02)11.</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2012(02)11</ArticleId><ArticleId IdType="pmc">PMC3275113</ArticleId><ArticleId IdType="pubmed">22358241</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;era M.C., Cardarelli P.M., Preston B.T., Witte A., Davis J.C., Jr. Type I Interferon Correlates with Serological and Clinical Manifestations of Sle. Ann. Rheum. Dis. 2005;64:1692&#x2013;1697. doi: 10.1136/ard.2004.033753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.033753</ArticleId><ArticleId IdType="pmc">PMC1755300</ArticleId><ArticleId IdType="pubmed">15843451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou Y., Isenberg D.A. Current Evidence for the Induction of Autoimmune Rheumatic Manifestations by Cytokine Therapy. Arthritis Rheum. 2000;43:1431&#x2013;1442. doi: 10.1002/1529-0131(200007)43:7&lt;1431::AID-ANR3&gt;3.0.CO;2-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200007)43:7&lt;1431::AID-ANR3&gt;3.0.CO;2-E</ArticleId><ArticleId IdType="pubmed">10902743</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda S.K., Kolbeck R., Sanjuan M.A. Plasmacytoid Dendritic Cells in Autoimmunity. Curr. Opin. Immunol. 2017;44:20&#x2013;25. doi: 10.1016/j.coi.2016.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2016.10.006</ArticleId><ArticleId IdType="pubmed">27855321</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovgren T., Eloranta M.L., Bave U., Alm G.V., Ronnblom L. Induction of Interferon-Alpha Production in Plasmacytoid Dendritic Cells by Immune Complexes Containing Nucleic Acid Released by Necrotic or Late Apoptotic Cells and Lupus Igg. Arthritis Rheum. 2004;50:1861&#x2013;1872. doi: 10.1002/art.20254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20254</ArticleId><ArticleId IdType="pubmed">15188363</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras A., Alase A., Antanaviciute A., Carr I.M., Yusof M.Y.M., Wittmann M., Emery P., Tsokos G.C., Vital E.M. Functionally Impaired Plasmacytoid Dendritic Cells and Non-Haematopoietic Sources of Type I Interferon Characterize Human Autoimmunity. Nat. Commun. 2020;11:6149. doi: 10.1038/s41467-020-19918-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19918-z</ArticleId><ArticleId IdType="pmc">PMC7708979</ArticleId><ArticleId IdType="pubmed">33262343</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras A., Wittmann M., Vital E.M. Emerging Concepts of Type I Interferons in Sle Pathogenesis and Therapy. Nat. Rev. Rheumatol. 2022;18:575&#x2013;590. doi: 10.1038/s41584-022-00826-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-022-00826-z</ArticleId><ArticleId IdType="pubmed">36097207</ArticleId></ArticleIdList></Reference><Reference><Citation>Md Yusof M.Y., Psarras A., El-Sherbiny Y.M., Hensor E.M.A., Dutton K., Ul-Hassan S., Zayat A.S., Shalbaf M., Alase A., Wittmann M., et al. Prediction of Autoimmune Connective Tissue Disease in an at-Risk Cohort: Prognostic Value of a Novel Two-Score System for Interferon Status. Ann. Rheum. Dis. 2018;77:1432&#x2013;1439. doi: 10.1136/annrheumdis-2018-213386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213386</ArticleId><ArticleId IdType="pmc">PMC6161671</ArticleId><ArticleId IdType="pubmed">29929956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherian T.S., Kariuki S.N., Franek B.S., Buyon J.P., Clancy R.M., Niewold T.B. Brief Report: Irf5 Systemic Lupus Erythematosus Risk Haplotype Is Associated with Asymptomatic Serologic Autoimmunity and Progression to Clinical Autoimmunity in Mothers of Children with Neonatal Lupus. Arthritis Rheum. 2012;64:3383&#x2013;3387. doi: 10.1002/art.34571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34571</ArticleId><ArticleId IdType="pmc">PMC3449035</ArticleId><ArticleId IdType="pubmed">22674082</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold T.B., Hua J., Lehman T.J., Harley J.B., Crow M.K. High Serum Ifn-Alpha Activity Is a Heritable Risk Factor for Systemic Lupus Erythematosus. Genes Immun. 2007;8:492&#x2013;502. doi: 10.1038/sj.gene.6364408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gene.6364408</ArticleId><ArticleId IdType="pmc">PMC2702174</ArticleId><ArticleId IdType="pubmed">17581626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., Munroe M.E., Guthridge J.M., Bean K.M., Fife D.A., Chen H., Slight-Webb S.R., Keith M.P., Harley J.B., James J.A. Dysregulation of Innate and Adaptive Serum Mediators Precedes Systemic Lupus Erythematosus Classification and Improves Prognostic Accuracy of Autoantibodies. J. Autoimmun. 2016;74:182&#x2013;193. doi: 10.1016/j.jaut.2016.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.06.001</ArticleId><ArticleId IdType="pmc">PMC5079766</ArticleId><ArticleId IdType="pubmed">27338520</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano G., Cafiero C., Divella C., Sallustio F., Gigante M., Pontrelli P., De Palma G., Rossini M., Grandaliano G., Gesualdo L. Local Synthesis of Interferon-Alpha in Lupus Nephritis Is Associated with Type I Interferons Signature and Lmp7 Induction in Renal Tubular Epithelial Cells. Arthritis Res. Ther. 2015;17:72. doi: 10.1186/s13075-015-0588-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0588-3</ArticleId><ArticleId IdType="pmc">PMC4389585</ArticleId><ArticleId IdType="pubmed">25889472</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Era M., Cisternas M.G., Smilek D.E., Straub L., Houssiau F.A., Cervera R., Rovin B.H., Mackay M. Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort. Arthritis Rheumatol. 2015;67:1305&#x2013;1313. doi: 10.1002/art.39026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39026</ArticleId><ArticleId IdType="pubmed">25605554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou F., Lauwerys B.R., Dall&#x2019;Era M., Mackay M., Rovin B., Cervera R., Houssiau F.A., Maintain Nephritis Trial Investigators A Proteinuria Cut-Off Level of 0.7 G/Day after 12 Months of Treatment Best Predicts Long-Term Renal Outcome in Lupus Nephritis: Data from the Maintain Nephritis Trial. Lupus Sci. Med. 2015;2:e000123. doi: 10.1136/lupus-2015-000123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2015-000123</ArticleId><ArticleId IdType="pmc">PMC4654096</ArticleId><ArticleId IdType="pubmed">26629352</ArticleId></ArticleIdList></Reference><Reference><Citation>Razaghi A., Brusselaers N., Bjornstedt M., Durand-Dubief M. Copy Number Alteration of the Interferon Gene Cluster in Cancer: Individual Patient Data Meta-Analysis Prospects to Personalized Immunotherapy. Neoplasia. 2021;23:1059&#x2013;1068. doi: 10.1016/j.neo.2021.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2021.08.004</ArticleId><ArticleId IdType="pmc">PMC8458777</ArticleId><ArticleId IdType="pubmed">34555656</ArticleId></ArticleIdList></Reference><Reference><Citation>Berthier C.C., Bethunaickan R., Gonzalez-Rivera T., Nair V., Ramanujam M., Zhang W., Bottinger E.P., Segerer S., Lindenmeyer M., Cohen C.D., et al. Cross-Species Transcriptional Network Analysis Defines Shared Inflammatory Responses in Murine and Human Lupus Nephritis. J. Immunol. 2012;189:988&#x2013;1001. doi: 10.4049/jimmunol.1103031.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1103031</ArticleId><ArticleId IdType="pmc">PMC3392438</ArticleId><ArticleId IdType="pubmed">22723521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirankarn N., Tangwattanachuleeporn M., Wongpiyabovorn J., Wongchinsri J., Avihingsanon Y. Genetic Association of Interferon-Alpha Subtypes 1, 2 and 5 in Systemic Lupus Erythematosus. Tissue Antigens. 2008;72:588&#x2013;592. doi: 10.1111/j.1399-0039.2008.01146.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0039.2008.01146.x</ArticleId><ArticleId IdType="pubmed">19000144</ArticleId></ArticleIdList></Reference><Reference><Citation>Der E., Ranabothu S., Suryawanshi H., Akat K.M., Clancy R., Morozov P., Kustagi M., Czuppa M., Izmirly P., Belmont H.M., et al. Single Cell Rna Sequencing to Dissect the Molecular Heterogeneity in Lupus Nephritis. JCI Insight. 2017;2:e93009. doi: 10.1172/jci.insight.93009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.93009</ArticleId><ArticleId IdType="pmc">PMC5414553</ArticleId><ArticleId IdType="pubmed">28469080</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Q., Zhao J., Qian X., Wong J.L., Kaufman K.M., Yu C.Y., Siew H.H., Group Tan Tock Seng Hospital Lupus Study. Mok M.Y., Harley J.B., et al. Association of a Functional Irf7 Variant with Systemic Lupus Erythematosus. Arthritis Rheum. 2011;63:749&#x2013;754. doi: 10.1002/art.30193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30193</ArticleId><ArticleId IdType="pmc">PMC3063317</ArticleId><ArticleId IdType="pubmed">21360504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampe D., Hakroush S., Tampe B. Dissecting Signalling Pathways Associated with Intrarenal Synthesis of Complement Components in Lupus Nephritis. RMD Open. 2022;8:e002517. doi: 10.1136/rmdopen-2022-002517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002517</ArticleId><ArticleId IdType="pmc">PMC9345095</ArticleId><ArticleId IdType="pubmed">35906025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampe D., Hakroush S., Tampe B. Molecular Signatures of Intrarenal Complement Receptors C3ar1 and C5ar1 Correlate with Renal Outcome in Human Lupus Nephritis. Lupus Sci. Med. 2022;9:e000831. doi: 10.1136/lupus-2022-000831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000831</ArticleId><ArticleId IdType="pmc">PMC9756185</ArticleId><ArticleId IdType="pubmed">36521939</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L., Osawe I., Puri T., Lambris J.D., Haas M., Quigg R.J. C5a Promotes Development of Experimental Lupus Nephritis Which Can Be Blocked with a Specific Receptor Antagonist. Eur. J. Immunol. 2005;35:2496&#x2013;2506. doi: 10.1002/eji.200526327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200526327</ArticleId><ArticleId IdType="pubmed">16052609</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E.F., Furie R., Tanaka Y., Bruce I.N., Askanase A.D., Richez C., Bae S.C., Brohawn P.Z., Pineda L., Berglind A., et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N. Engl. J. Med. 2020;382:211&#x2013;221. doi: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L., Oganesyan V., Wu H., Dall&#x2019;Acqua W.F., Damschroder M.M. Molecular Basis for Antagonistic Activity of Anifrolumab, an Anti-Interferon-Alpha Receptor 1 Antibody. MAbs. 2015;7:428&#x2013;439. doi: 10.1080/19420862.2015.1007810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2015.1007810</ArticleId><ArticleId IdType="pmc">PMC4622752</ArticleId><ArticleId IdType="pubmed">25606664</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>